{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T15:28:00Z","timestamp":1749137280757,"version":"3.37.3"},"reference-count":16,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":84,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","onlinecjc.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cjca.2024.07.002","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T06:17:40Z","timestamp":1720937860000},"page":"2171-2179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4126-1285","authenticated-orcid":false,"given":"John W.","family":"Eikelboom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qilong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William F.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart J.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Scheier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Muehlhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1kos F.","family":"Pap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrikant I.","family":"Bangdiwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2024.07.002_bib1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.07.002_bib2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.cjca.2017.06.001","article-title":"Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial","volume":"33","author":"Bosch","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2024.07.002_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/CIRCULATIONAHA.120.046048","article-title":"The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease","volume":"142","author":"Steffel","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.07.002_bib4","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.07.002_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.07.002_bib6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.07.002_bib7","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1093\/eurheartj\/ehaa665","article-title":"The win ratio approach for composite endpoints: practical guidance based on previous experience","volume":"41","author":"Redfors","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.07.002_bib8","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1177\/09622802221084134","article-title":"On recurrent-event win ratio","volume":"31","author":"Mao","year":"2022","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.cjca.2024.07.002_bib9","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/j.jacc.2019.03.479","article-title":"Monitoring emerging data from the COMPASS trial of an antithrombotic agent","volume":"73","author":"Cairns","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.07.002_bib10","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1016\/j.jacc.2019.02.079","article-title":"Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial","volume":"73","author":"Anand","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.07.002_bib11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jchf.2020.02.010","article-title":"Use of the win ratio in cardiovascular trials","volume":"8","author":"Ferreira","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2024.07.002_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.cjca.2024.07.002_bib13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.07.002_bib14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacbts.2023.05.004","article-title":"Fallacies of using the win ratio in cardiovascular trials: challenges and solutions","volume":"8","author":"Ajufo","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cjca.2024.07.002_bib15","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/STROKEAHA.110.600106","article-title":"Weighting components of composite end points in clinical trials: an approach using disability-adjusted life-years","volume":"42","author":"Hong","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2024.07.002_bib16","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jacc.2013.05.042","article-title":"Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation","volume":"62","author":"Eikelboom","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X24005221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X24005221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T07:44:33Z","timestamp":1738223073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X24005221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0828282X24005221"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2024.07.002","relation":{},"ISSN":["0828-282X"],"issn-type":[{"type":"print","value":"0828-282X"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2024.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}